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SUMMARY
In kidney transplant recipients (KTRs), BK polyomavirus (BKPyV) replica-
tion may progress to polyomavirus-associated nephropathy (PVAN). In
this retrospective study, we assessed the chemokine CXCL10 in urine and
blood samples consecutively acquired from 85 KTRs who displayed differ-
ent stages of BKPyV replication and eventually developed PVAN. In paral-
lel to progression toward PVAN, CXCL10 gradually increased in blood and
urine, from baseline (prior to virus replication) to BKPyV DNAuria (me-
dian increase in blood: 42.15 pg/ml, P = 0.0156), from mere DNAuria to
low- and high-level BKPyV DNAemia (median increase: 52.60 and
87.26 pg/ml, P = 0.0010 and P = 0.0002, respectively) and peaked with
histologically confirmed PVAN (median increase: 145.00 pg/ml,
P < 0.0001). CXCL10 blood and urine levels significantly differed among
KTRs with respect to simultaneous presence of human cytomegalovirus
(P < 0.001) as well as in relation to the clinical severity of respective
BKPyV DNAemia episodes (P = 0.0195). CXCL-10 concentrations were
particularly lower in KTRs in whom BKPyV DNAemia remained without
clinical evidence for PVAN, as compared to individuals who displayed high
decoy cell levels, decreased renal function and/or biopsy-proven PVAN
(median blood concentration: 266.97 vs. 426.42 pg/ml, P = 0.0282). In
conclusion, in KTRs CXCL10 rises in parallel to BKPyV replication and
correlates with the gradual development of PVAN.
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Introduction
BK virus (BKPyV) and JC virus (JCPyV), two human
polyomaviruses, cause persistent infection, with the uri-
nary tract as most relevant latency site [1]. Since cellular
immunity plays a key role in control of these viruses,
immunosuppressive treatment after kidney transplanta-
tion (KTX) may lead to their reactivation, usually first
indicated by asymptomatic viruria [2–8]. Especially
when viruria is sustained in the long term, it may be
followed by viremia, and progression of viral replication
is subsequently indicated by occurrence of high viral
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loads in urine and blood, which may finally result in
significant inflammation, parenchymal injury, and
symptomatic disease, termed as polyomavirus-associated
nephropathy (PVAN) [2–4,9–12].
Although BKPyV is the main causative agent, JCPyV
may also trigger PVAN [5,13]. Quantitative measure-
ment of BKPyV with or without JCPyV DNA in urine
and blood is therefore commonly undertaken during
the post-transplant surveillance [2,3,14,15]. Additional
correlates of clinical progression are emergence of decoy
cells in the urinary sediment, an indicator for cytopathic
effects due to urothelial cell infection, the detection of
viral aggregates by the Haufen test, BKPyV VP1 mRNA
as well as histological evidence of viral inclusions, tubu-
lar injury, and inflammatory infiltrates [2–4,16–18].
Host factors, as well as viral determinants, account
for the complex pathogenesis of PVAN [3,4]. Immune
responses, which on one hand, are essential to control
viral replication may on the other hand mediate renal
injury. In this process, like in all inflammatory pro-
cesses, chemokines, structurally related, small chemotac-
tic cytokines orchestrate cell–cell signaling and immune
cell trafficking [19,20]. Since chemokines shape immune
responses against specific pathogens by recruiting par-
ticular subsets of leukocytes to the infection site, they
play an essential role and may be used as inflammatory
biomarkers in viral diseases [21–23].
In this study, we longitudinally assessed levels of
CXC-ligand 10 (CXCL10), a chemokine which attracts
and activates immune cells with a cytokine profile of
T-helper cells Type 1 (Th1), aiming to determine
whether CXCL10 correlates with an increase and clinical
progression of BKPyV replication [24–26]. Our analysis
also included the chemokines CCL8, CXCL16, and
CCL20, candidate markers for outcome and severity of
human cytomegalovirus (HCMV) infections in solid
organ recipients [22,23,27].
Materials and methods
Patients and sample acquisition
This retrospective study included pairs of blood and
urine samples from a total of 95 KTRs (35 female, 60
male) including controls, who underwent KTX between
March 2008 and September 2014. All KTRs underwent
virological routine testing which consisted of PCR anal-
yses for BKPyV and JCPyV DNA in urine and blood,
collected pairwise on the same day of the post-trans-
plant follow-up, respectively, and HCMV DNA in
blood. Eighty-five patients were selected for the study
by retrospective review of virological test results and
were included when at least one episode of BKPyV
DNAemia with DNA loads ≥1000 copies/ml occurred
during the post-transplant follow-up. Ten KTRs, who
underwent transplantation and post-transplant surveil-
lance during the same time period, served as controls
since they lacked any evidence of BKPyV, JCPyV, or
HCMV replication (see Table S1). Further information
on the immunosuppressive treatment, the schedule of
sample acquisition and virological routine testing as well
as on the storage of samples is given in Supplemental
Material and Methods. Sample collection and storage as
well as the whole study protocol was approved by the
local ethics committee of Medical University of Vienna,
which concluded that no written informed consent from
the patients was required (EK1035/2016, EK2064/2016).
The study was performed in accordance with the Hel-
sinki Declaration.
Quantitative PCR
Information on the protocols used for quantitative
BKPyV, JCPyV, and HCMV PCR analyses is given in
Appendix S1.
Criteria for grouping patients and selection of
samples
Out of the 85 KTRs, who were included in the study
because they displayed at least one episode of BKPyV
DNAemia, 56 displayed BKPyV DNAemia in the absence
of significant JCPyV and HCMV DNAemia. Thirteen
KTRs simultaneously developed BKPyV and JCPyV
DNAemia (>1000 copies/ml, respectively) and 16 simul-
taneously developed BKPyV and HCMV DNAemia.
Among these groups, there was no significant difference
with respect to gender, age, transplant type, donor char-
acteristics, cold ischemia time, delayed graft function,
HLA-mismatches, AB0 and HLA-incompatibilities, dura-
tion of follow-up and the median time point BKPyV
DNAemia occurred (Table S1).
To assess individual CXCL-10 kinetics during pro-
gression of BKPyV replication, we retrieved and ana-
lyzed 148 specific blood/urine sample pairs, collected
from the 56 KTRs with mere BKPyV HCMV DNAemia
due to routine testing. These samples specifically ful-
filled the inclusion requirement that they had been col-
lected during different stages of BKPyV replication
(mean number of sample pairs per patient: 2.64, range:
2–4). As shown in Table 1, these stages were defined as:
(i) baseline (before BKPyV detection, with undetectable
556 Transplant International 2020; 33: 555–566
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BKPyV, JCPyV, and HCMV DNA in urine and blood,
no evidence for any other infection nor rejection, nor-
mal levels of C-reactive protein and leukocytes, normal
urinary cytology, no drop in renal function), (ii) BKPyV
detection only in urine (BKPyV DNAuria) but not in
blood, (iii) BKPyV DNAuria plus low-level BKPyV
DNAemia (blood DNA levels <1000 copies/ml), (iv)
BKPyV DNAuria plus BKPyV DNAemia (blood DNA
levels ≥1000 copies/ml) but no significant decoy cell
levels, (v) BKPyV DNAemia (>1000 copies/ml) together
with detection of decoy cell levels >20%, a decrease of
eGFR  histological evidence for PVAN. The mean
sampling intervals are shown in Table 1. When multiple
samples were acquired from one patient during the
same stage of BKPyV replication, only the initial sample
that fulfilled the respective criteria was selected for the
study.
In order to compare chemokine levels among individ-
ual patients, the 56 KTRs with mere BKPyV DNAemia
were sub-grouped based on the clinical severity of the
respective BKPyV DNAemia episode. Although their
BKPyV DNA loads exceeded 1000 copies/ml, 9 of the 56
KTRs displayed no significant decoy cell levels (<5%) in
urinary sediment during any BKPyV DNAemia episode,
renal function remained stable and no biopsy was there-
fore performed during the entire follow-up. The other 47
KTRs, in contrast, displayed at least one BKPyV DNAe-
mia episode in which significant decoy cell levels (defined
as >20%) were concomitantly detected. Of those 47, 23
(48.9%) additionally showed a ≥15% decrease of esti-
mated glomerular filtration rate (eGFR), as compared to
the mean of three measurements which immediately pre-
ceded the initial occurrence of the respective high-level
DNAemia episode (median interval: 41 days, range: 13–
98). In 15 patients, PVAN was confirmed with a renal
biopsy obtained within a week before or after blood/urine
sampling. In the remaining KTRs, no biopsies were per-
formed within this time period.
In addition to the 47 patients with mere BKPyV
DNAemia, all 13 KTRs, who simultaneously displayed
high-level BKPyV and JCPyV DNAemia, showed decoy
cells >20%. An eGFR decrease occurred in 6 (46.2%)
and PVAN was histologically confirmed in 5 of these 13
KTRs.
Histological confirmation of PVAN was based on the
detection of injured tubules with or without interstitial
nephritis, viral inclusion bodies, and/or positive SV40
T-Antigen staining [28]. In all biopsies with confirmed
PVAN, pathologists specifically described no histological
evidence for rejection [29]. However, 10 KTRs with
high-level BKPyV DNAemia subsequently developed
allograft rejection during the same BKPyV DNAemia
episode, which was confirmed by histology using Banff
criteria (borderline T-cell-mediated rejection: n = 7,
CD4d+ rejection: n = 1, acute cellular rejection: n = 1,
T-cell-mediated rejection 2a: n = 1) [29].
As described, urine/blood sample pairs from 10
KTRs who did not display any BKPyV, JCPyV, and
HCMV replication were included as controls, and sam-
ples from these controls fulfilled the same criteria as
baseline samples (C-reactive protein and leukocytes in
normal range, normal urinary cytology, and no eGFR
decrease).
Quantification of CXCL10, CCL8, CXCL16, and
CCL20
CXCL10, CCL8, CXCL16, and CCL20 were quantified
by a commercially available ELISA test and LuminexTM
xMAP technology [30]. More information is given in
Appendix S1.
Statistical methods
Within-patient comparisons of CXCL-10 in blood and
urine were performed using paired nonparametric
t-tests (Wilcoxon matched-pairs signed-rank test). Dif-
ferences in CXCL10, CCL8, CCL20, and CXCL16 con-
centrations (including blood/urine ratios) between
KTRs with BKPyV DNAemia with and without progres-
sion to PVAN as well as among patients with additional
JCPyV, HCMV DNAemia were compared by unpaired
nonparametric Kruskal–Wallis and Dunn´s multiple
comparison tests. CXCL10 between baseline samples
and control individuals was compared by Mann–Whit-
ney t-test. Effect sizes are reported as dCohen. Receiver
operating characteristic (ROC) analyses were performed
to analyze the association of CXCL10 with high-level
BKPyV DNAemia, clinical manifestations, and/or histo-
logical evidence of PVAN. For all statistical tests, a two-
tailed P-value of <0.05 was considered statistically sig-
nificant. GRAPHPAD PRISM version 8.0 software was used
for statistical analyses.
Results
CXCL10 in blood and urine during progression of
BKPyV replication
First, we analyzed whether progression of BKPyV repli-
cation toward DNAemia and PVAN was associated with
a response of the inflammatory chemokine CXCL10.
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Therefore, we quantified CXCL10 in 148 pairs of urine
and blood samples acquired from 56 KTRs with BKPyV
(but not JCPyV or HCMV) DNAemia at multiple time
points and during different stages of BKPyV replication
(Table 1).
As shown in Fig. 1a and Table S2, from first BKPyV
detection in urine toward histologically proven PVAN,
we observed a gradual increase of CXCL10 in blood.
CXCL10 concentrations significantly increased from
baseline to BKPyV DNAuria only (median increase:
42.15 pg/ml, 95% CI: 9.11–151.84, P = 0.016). This
CXCL10 baseline concentration (before BKPyV detec-
tion) did not significantly differ from the one in con-
trols who did not display any BKPyV, JCPyV, or
HCMV detection during follow-up (median difference:
0.81 pg/ml, 95% CI: 32.72 to 21.98, P = 0.74).
CXCL10 in blood further rose when in addition to mere
BKPyV DNAuria low-level DNAemia emerged (median
increase: 52.60 pg/ml, 95% CI: 41.55–78.82, P = 0.001)
and further increased when low-level DNAemia pro-
gressed to DNA loads ≥1000 copies/ml, but no evidence
for PVAN was yet detected (decoy cells <20%, no eGFR
decrease; median increase: 87.26 pg/ml, 95% CI: 55.42–
153.51, P = 0.0002). CXCL10 in blood finally peaked
when BKPyV DNAuria and DNAemia concomitantly
occurred with clinical manifestations (significant decoy
cell levels  eGFR decrease) and/or histological evi-
dence of PVAN (median increase: 145.00 pg/ml, 95%
CI: 120.20–227.83, P < 0.0001).
Next, we analyzed whether progression of BKPyV
replication toward DNAemia and PVAN was associated
with an inflammatory CXCL10 response in urine analo-
gously to blood concentrations. Therefore, we quantified
CXCL10 in urine samples obtained pairwise with blood
samples and found that CXCL10 urine concentrations
also increased due to progression of BKPyV replication.
As shown in Fig. 1b and Table S2, CXCL10 in urine
rose from baseline to BKPyV DNAuria alone (median
increase: 14.15 pg/ml, 95% CI: 1.48 to 38.23,
P = 0.0223) and increased from this to low-level DNAe-
mia (median increase: 36.44 pg/ml, 95% CI: 16.59–
80.91, P = 0.001). The CXCL10 urine concentration fur-
ther increased from low-level BKPyV DNAemia when
viral DNA loads exceeded 1000 copies/ml but no clini-
cal manifestations of PVAN were observed yet (median
increase: 87.59 pg/ml, 95% CI: 39.02–148.07,
P = 0.0005). CXCL10 in urine finally peaked when, in
addition to DNAemia, significant levels of decoy cells, a
decrease of eGFR and/or histological evidence for PVAN
were detected (median increase: 173.50 pg/ml, 95% CI:
129.27–280.41, P < 0.0001).
The individual blood/urine ratio of the CXCL10 con-
centration did not significantly change during different
stages of BKPyV replication until an eGFR decrease
occurred and/or biopsy-proven PVAN developed. As
compared to the other stages, evidence for PVAN was
associated with a significant decrease of the ratio due to
a disproportionately strong increase of urine CXCL-10
levels (median change of the blood/urine ratio: 0.89,
95% CI: 7.38 to 0.69, P = 0.0042).
CXCL-10 levels in additional JCPyV, HCMV
DNAemia, and rejection
Then, we compared CXCL10 in blood at BKPyV DNAe-
mia (>1000 copies/ml) with the CXCL-10 concentration
in 13 KTRs who additionally displayed JCPyV DNAe-
mia (>1000 copies/ml), as well as in 16 KTRs with con-
comitant HCMV DNAemia. Of note, CXCL10 in blood
showed a trend for higher concentrations in KTRs with
additional JCPyV DNAemia than in patients with mere
BKPyV DNAemia (median concentration: 466.03 vs.
404.44 pg/ml, 95% CI: 430.33–613.59 vs. 385.60–473.74,
P = 0.0631, Fig. 2a). The highest CXCL10 blood con-
centrations were however encountered in KTRs who, in
addition to BKPyV, displayed HCMV DNAemia (me-
dian concentration: 892.87 pg/ml, 95% CI: 590.29–
2126.10, P < 0.0001 vs. BKPyV DNAemia, P = 0.0325
vs BKPyV and JCPyV DNAemia, dCohen: 1.50, Fig. 2a,
Table S2).
Of note, there was a significant increase of the
CXCL-10 blood concentration when 10 KTRs of our
study cohort displayed BKPyV DNAemia and subse-
quently developed additional allograft rejection (median
increase: 151.94 pg/ml, 95% CI: 45.47–542.50,
P = 0.002, Fig. 2a).
Analogously to blood levels, the CXCL-10 urine con-
centration was slightly higher in KTRs, who in addition
to BKPyV DNAemia displayed JCPyV DNAemia than in
KTRs with BKPyV DNAemia alone (median concentra-
tion: 422.15 vs. 381.26 pg/ml, 95% CI: 325.48–726.24
vs. 281.15–386.61, P = 0.0497, dCohen: 0.77). In contrast
to blood levels, CXCL10 in urine did not significantly
differ between KTRs with BKPyV DNAemia and those
who additionally displayed HCMV DNAemia (median
concentration: 384.59 pg/ml, 95% CI: 259.27–485.82,
P = 0.4290 vs. mere BKPyV, P = 0.3291 vs BKPyV and
JCPyV DNAemia, Fig. 2b). Therefore, a significantly
higher CXCL-10 blood/urine ratio was observed in
KTRs with additional HCMV DNAemia, as compared
to patients with BKPyV  JCPyV DNAemia (median
ratios: 1.12 for mere BKPyV, 1.10 for BKPyV and
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JCPyV and 3.00 for additional HCMV DNAemia,
P = 0.008, dCohen: 0.90).
In contrast and analogously to blood levels, there was a
significant increase of the CXCL-10 urine concentration
when 10 KTRs with BKPyV DNAemia subsequently
developed additional allograft rejection (median increase:
81.22 pg/ml, 95% CI: 39.78–169.11, P = 0.0020, Fig. 2b).
CXCL10 differences in relation to BKPyV-associated
clinical manifestations
Next, we analyzed whether CXCL10 in blood and urine
differed among KTRs with respect to the most severe
clinical manifestation which concomitantly emerged
with BKPyV DNAemia during the follow-up. Therefore,
KTRs with episodes of BKPyV DNAemia were grouped
as shown in Table 2. In 20 KTRs, the most severe mani-
festation of BKPV (JCPyV) replication was histological
evidence of PVAN; in 12 KTRs, in whom no biopsy was
performed, the most severe clinical manifestation was a
decrease of eGFR. In these patients, the simultaneously
detected decoy cell levels were high (>30%), while in 9
KTRs, in contrast, BKPyV DNAemia was associated
with no significant levels of decoy cells (<5%) and
eGFR remained stable. Although BKPyV DNA loads
exceeded 1000 copies/ml in these patients, viral loads
were significantly lower than in KTRs with histological
and/or clinical evidence of PVAN (Table 2). Absolute
eGFR values at the time point of BKPyV DNAemia
were also significantly lower in the 20 KTRs with histo-
logically verified PVAN than in the nine patients with
low decoy cell levels and lower BKPyV DNA loads (me-
dian difference: 11.69 ml/min/1.73, 95% CI: 23.88
to 1.92, P = 0.0213, dCohen = 0.96).
As shown in Fig. 3a and Table S2, CXCL10 in blood
was significantly lower in KTRs with lower DNA loads,
lower decoy cell levels (<5%), and no eGFR decrease, as
compared to KTRs with higher viral loads, higher decoy
cell levels and a simultaneous decrease of eGFR (median
concentration: 266.97 vs. 436.02 pg/ml, 95% CI:
196.09–362.66 vs. 356.77–547.10, P = 0.0422). Peak
CXCL-10 blood concentrations, however, were observed
Figure 1 Increase of inflammatory CXCL10 due to progression of BKPyV replication. In 56 KTRs, CXCL10 gradually increases along with pro-
gression of BKPyV replication toward PVAN. (a) Blood CXCL10 concentrations increase from baseline (prior to virus replication; n = 16 samples)
to exclusive BKPyV DNAuria (BKPyV detection only in urine but not in blood, n = 33 samples). They further rise when low-level BKPyV DNAe-
mia additionally emerges (n = 21 samples) and even more increase when BKPyV DNA loads subsequently exceed 1000 copies/ml (n = 31 sam-
ples). CXCL10 in blood finally peaks when BKPyV DNAuria, DNAemia, urinary decoy cells (>20%), an eGFR decrease, and histologically proven
PVAN are simultaneously detectable (n = 47 samples). (b) Analogously to the blood concentration, CXCL10 in urine increases from baseline to
exclusive BKPyV DNAuria, from BKPyV DNAuria to low-level DNAemia and further to DNaemia ≥ 1000 copies/ml without PVAN. Urinary
CXCL10 also peaks when, in addition to BKPyV DNAemia, decoy cells, an eGFR decrease, and histological evidence of PVAN simultaneously
emerge. Gray bars indicate median CXCL10 concentrations.
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in KTRs in whom PVAN was histologically verified
(median concentration: 426.42 pg/ml, 95% CI: 375.39–
557.33, P = 0.0282, dCohen = 0.86).
In addition, CXCL10 in urine was higher during
BKPyV DNAemia in KTRs who displayed higher DNA
loads, significant levels of decoy cells and an eGFR
decrease than in KTRs who did not (median concentra-
tion: 345.42 vs. 168.09 pg/ml, 95% CIs: 254.73–538.69
vs. 115.93–234.00, P = 0.0447) and peaked in patients
in whom PVAN was verified histologically (median con-
centration: 412.97 pg/ml, 95% CI: 291.90–571.03,
P = 0.0204, dCohen = 0.885, Fig. 3b).
Figure 2 CXCL-10 levels in additional JCPyV and HCMV DNAemia and rejection. (a) Patients (n = 13) who, in addition to BKPyV DNAemia dis-
play JCPyV DNAemia (>1000 copies/ml, respectively), show a trend toward higher CXCL10 blood concentrations than those without JCPyV
(n = 47). The highest CXCL10 blood concentrations are found in KTRs who, in addition to BKPyV DNAemia, show DNAemia of HCMV
(n = 16). Of note, CXCL-10 blood concentration significantly increases when 10 KTRs with BKPyV DNAemia subsequently develop additional
allograft rejection. (b) KTRs who, in addition to BKPyV display JCPyV DNAemia, also show a slightly higher CXCL10 urine concentration than
those without JCPyV DNAemia. The CXCL10 concentration in urine does not significantly differ among KTRs with BKPyV DNAemia (with or
without JCPyV DNAemia) and those with additional HCMV DNAemia. Analogously to blood levels, CXCL10 in urine significantly increases
when KTRs with BKPyV DNAemia subsequently develop additional allograft rejection.
Table 2. Patient groups based on the clinical severity of BKPyV-associated manifestation during the follow-up.
Groups and differentiation
criteria
Decoy cells < 5%,
no eGFRdrop eGFR drop
Histologically verified
PVAN
Difference among
the groups (P)
Number of patients (n) 9 12 20
BKPyV DNA in blood
(median,range; copies/ml)
2.0 9 103,
1.0 9 103–2.7 9 104
3.2 9 104,
5.3 9 103–1.1 9 106
1.4 9 105,
1.1 9 104–4.2 9 108
<0.0001
Decoy cells in urinary sediment
(median, range; %)
1,
0–5
45,
30–95
90,
30–98
<0.0001
Drop of renal function (≥15%
decrease of eGFR, as compared
to mean of the three preceding
measurements)
0/9 12/12 17/20 <0.0001
PVAN verified in histology (biopsy
within 1 week before/after
sample acquisition)
No biopsy performed No biopsy performed 20/20 <0.0001
BKPyV, BK polyomavirus; eGFR, estimated glomerular filtration rate; PVAN, polyomavirus-associated nephropathy.
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Association of CXCL10 with high-level BKPyV
DNAemia and BKPyV-associated disease
Then, we analyzed CXCL10 levels in high-level BKPyV
DNAemia (presumptive for PVAN) using
10 000 copies/ml (but not decoy cell levels or an eGFR
decrease) as reference. Out of the 56 KTRs with peak
BKPyV DNA levels >1000 copies/ml, 42 KTRs displayed
viral loads >10 000 copies/ml, while 14 patients did not.
CXCL10 serum concentrations were significantly higher
in these 42 KTRs with peak DNA loads >10 000 copies/
ml than in the 14 KTRs with lower viral loads (median
CXCL10 concentration: 411.22 vs. 310.15 pg/ml, 95%
CI: 438.77–162.82 vs. 318.64–116.81, P = 0.0122,
dCohen = 0.70). For CXCL10 in urine, however, no sta-
tistically significant difference was observed (median
concentration: 343.50 vs. 292.91 pg/ml, 95% CI:
258.75–366.52 vs. 194.23–414.98, P = 0.7152). As shown
in Fig. S1, we also performed ROC analyses to evaluate
the association of the CXCL-10 concentration with
manifestations of BKPyV-associated disease. Of note,
the area under the curve (AUC) was slightly higher
when clinical manifestations and/or histological evi-
dence PVAN rather than high-level BKPyV DNAemia
>10 000 copies/ml were used as a reference (Table 2;
Fig. S1).
Figure 3 CXCL10 in relation to BKPyV-associated clinical manifestations. (a) In episodes of significant BKPyV DNAemia (DNA loads exceeding
1000 copies/ml) CXCL10 in blood was levels are significantly lower in KTRs who display lower BKPyV DNA loads, lower decoy cell levels
(<5%), and no eGFR decrease (n = 9), as compared to KTRs who display a simultaneous eGFR decrease, higher viral loads, and higher decoy
cell levels (>30%; n = 12), as well as in KTRs in whom PVAN is concomitantly verified by histology (n = 20). (b) Also, CXCL10 in urine is signif-
icantly higher in KTRs who display an eGFR decrease, higher viral DNA loads, and significant higher levels of decoy cells as well as in KTRs in
whom PVAN is histologically verified, as compared to patients with lower BKPyV DNA loads, no significant decoy cell levels and no concurrent
eGFR decrease.
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CCL8, CXCL16, and CCL20 blood levels in relation to
BKPyV-associated clinical manifestations
Next, we investigated whether concentrations of other
T-cell associated chemokines differed in relation to the
severity of BKPyV replication. Therefore, we quantified
CCL8, CXCL16, and CCL20 in blood in the groups of
KTR as shown in Table 2 and found that CCL8 blood con-
centrations were significantly higher in KTRs with BKPyV
DNAemia who displayed higher viral loads, significant
levels of decoy cells, and an eGFR decrease as well as in
KTRs who displayed histological evidence of PVAN as
compared to KTRs who did not (median concentrations:
59.40 vs. 57.79 vs. 32.34 pg/ml, 95% CIs: 41.27–99.28 vs.
50.49–76.80 vs. 15.54–47.52, P = 0.0491 vs. eGFR
decrease, P = 0.0205 vs. PVAN, dCohen: 0.88, Fig. 4a). In
contrast, CXCL16 and CCL-20 in blood did not signifi-
cantly differ among KTRs with BKPyV DNAemia with
respect to the severity of clinical manifestations associated
with respective BKPyV DNAemia episodes (Fig. 4b,c).
Discussion
In this study, we longitudinally analyzed CXCL10 in
KTRs during different stages of BKPyV replication and
demonstrate that, along with progression of BKPyV
replication, CXCL10 in blood and urine gradually
increases, from viral DNAuria over low- and high-level
DNAemia to a decrease of renal function and histological
evidence PVAN. These findings suggest that CXCL10
concentrations in blood and urine might reflect the step-
wise increase of inflammation and development of poly-
omavirus-associated disease in KTRs, a fact that should
specifically be considered when CXCL10 is proposed as
particular marker of allograft rejection [25,31–37].
Indeed, CXCL10 attracts and activates T-cells with a
Th1 cytokine profile, and since its production can again
be induced upon stimulation with Th1-derived cytokines
like interferon-c (IFN-c), it apparently participates in a
positive feedback loop [24,25]. CXCL10 is thus essential
to elicit a Th1-shaped cellular immune response against
viruses, but on the other hand, contributes to tissue
inflammation and injury [38]. Consequently, CXCL10
has been proposed as marker of immune activation,
severity, and therapy response in diverse viral diseases
but also of allograft rejection [21,25,30–36].
In previous studies, elevated CXCL10 urine concen-
trations were equally detected when KTRs displayed
BKPyV nephritis or DNAemia as well as allograft rejec-
tion [33,34,39]. Elevated blood concentrations were
encountered in KTRs with BKPyV detection in urine
and/or serum [8,33,40]. Our present data are in
Figure 4 CCL8, CXCL16, and CCL20 in blood in relation to BKPyV-associated clinical manifestations. (a) CCL8 in blood is significantly higher in
KTRs with BKPyV DNAemia (DNA loads exceeding 1000 copies/ml) who display an eGFR decrease, higher viral loads, and higher decoy cell levels
(n = 12) as well as histologically confirmed PVAN (n = 20), as compared to KTRs who display lower BKPyV DNA loads, lower levels of decoy cells,
and no concurrent eGFR decrease (n = 9). (b) CXCL16 and (c) CCL20 in blood do not significantly differ in KTRs with BKPyV DNAemia in relation
to levels of BKPyV DNA, decoy cells, the concurrent presence of an eGFR decrease as well as to histological evidence of PVAN.
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accordance with and extend these former findings, indi-
cating that a CXCL10 increase due to BKPyV can be
equally detected in urine and blood, occurs stepwise
and in proportion to the extent of viral replication, and
correlates with a decrease of renal function and histo-
logical verification of PVAN. Of note, a similar observa-
tion has been made for Interleukin-6, which increases
with rising BKPyV loads [41].
The gradual CXCL10 response we observed here, not
only discloses that intrarenal BKPyV replication and
CXCL10 secretion into urine and blood are functionally
linked, but suggests its cumulative inflammatory effect on
the occurrence of nephropathy. A correlation of urinary
CXCL10 levels with tubule-interstitial inflammation and
grade of tubulitis was previously reported, while upregu-
lation of CXCL10 genes could pose the underlying func-
tional background in patients with PVAN [33,42–44].
Our particular finding that not only urine but also
blood CXCL10 concentrations were elevated over base-
line during mere BKPyV DNAuria, furthermore high-
lights that even early, clinically silent, and locally
restricted BKPyV replication in the allograft is sufficient
to elicit a systemic CXCL10 rise and trigger inflamma-
tion. Since increased CXCL10 levels have been associ-
ated with long-term allograft dysfunction in KTRs, an
increased CXCL10 concentration due to low level but
sustained BKPyV replication could also possibly
adversely influence allograft survival [33,35,36,39,45,46].
Correspondingly, a constantly low CXCL10 urinary con-
centration was recently correlated with histologically
stable allografts and freedom of rejection [47]. Thus, it
is indeed possible that CXCL10 might serve as inflam-
matory marker to individualize immunosuppressive
treatment, this, however, requires further studies.
Although we demonstrated that CXCL10 gradually
increases along with BKPyV replication, the potential use
of CXCL10 as biomarker for PVAN may be limited. Of
note, allograft rejection may also be associated with
increased CXCL10 levels, whereby multiple studies
have proposed CXCL10 as a rejection marker
[25,31,32,39,42,46]. In this regard, our observation that
CXCL10 in blood and urine already increased for mere
BKPyV DNAuria, particularly suggests that absence of
BKPyV should be verified, before a CXCL10 rise can be
considered an indicator of allograft rejection. Indeed, we
observed that CXCL10 further increased when KTRs with
BKPyV DNAemia subsequently developed allograft rejec-
tion, but considering that CXCL10 responses might vary
among individuals, it seems questionable whether quanti-
tative differences might ultimately discriminate between
PVAN and rejection.
With this regard, we also demonstrated that other
viral agents influence the CXCL10 concentration in
KTRs, and especially HCMV DNAemia showed a
strong cumulative effect on CXCL10 blood but not
urine levels, an observation that is in line with recent
findings that CXCL10 in blood but not in urine
increased in KTRs with histologically verified HCMV
infection [33]. Of note, we previously demonstrated
that intrapulmonal HCMV replication in lung trans-
plant recipients caused a systemic rise of CXCL10 in
blood, while in bronchoalveolar fluid it only increased
when inflammatory airway obstruction simultaneously
occurred [21]. In the KTRs with HCMV DNAemia we
investigated, the renal allograft might thus not have
been the primary site of replication or inflammation.
Finally, it is noteworthy that among the T-cell-associ-
ated chemokines, we investigated, only CXCL10 and
CCL8 significantly correlated with progression of
BKPyV replication, while CCL20 and CXCL16 did not.
Elevated CXCL16 concentrations were found in KTRs
with hypertensive kidney injury, while increased CCL20
levels were detected in clinically manifest allograft rejec-
tion [48,49]. Interestingly, in vitro data demonstrated
that renal tubular epithelial cells, when stimulated with
IFN-c, strongly upregulate CXCL10 but not CCL20
[50]. Thus, due to the effect of virally induced Th1
cytokines, CXCL10 might predominate over CCL20
during BKPyV replication, indicating that different virus
infections might indeed elicit different patterns of che-
mokine responses.
The lack of baseline samples and histological data
for the whole cohort certainly pose limitations of this
study. Nonetheless, in summary, the provided data
demonstrate that CXCL10 in urine and blood already
rises during early BKPyV replication, gradually
increases in proportion with the extent of viral replica-
tion and correlates with the progression toward PVAN.
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